Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

Blood

Volumn 125, Issue 19, 2015, Pages 2885-2892

  Popat, Uday ^a   Mehta, Rohtesh S ^a   Rezvani, Katayoun ^a   Fox, Patricia ^a   Kondo, Kayo ^a   Marin, David ^a   McNiece, Ian ^a   Oran, Betul ^a   Hosing, Chitra ^a   Olson, Amanda ^a   Parmar, Simrit ^a   Shah, Nina ^a   Andreeff, Michael ^a   Kebriaei, Partow ^a   Kaur, Indreshpal ^a   Yvon, Eric ^a   De Lima, Marcos ^b   Cooper, Laurence J N ^a   Tewari, Priti ^a   Champlin, Richard E ^a   Nieto, Yago ^a   Andersson, Borje S ^a   Alousi, Amin ^a   Jones, Roy B ^a   Qazilbash, Muzaffar H ^a   Bashir, Qaiser ^a   Ciurea, Stefan ^a   Ahmed, Sairah ^a   Anderlini, Paolo ^a   Bosque, Doyle ^a   Bollard, Catherine ^c   Molldrem, Jeffrey J ^a   Chen, Julianne ^a   Rondon, Gabriela ^a   Thomas, Michael ^a   Miller, Leonard ^d   Wolpe, Steve ^d   Simmons, Paul ^e   Robinson, Simon ^a   Zweidler McKay, Patrick A ^b   Shpall, Elizabeth J ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d Preclinical Research Department Targazyme Inc   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CLOFARABINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FILGRASTIM; FLUDARABINE; FUCOSYLTRANSFERASE; GUANOSINE DIPHOSPHATE FUCOSE; MELPHALAN; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; FUCOSE; PADGEM PROTEIN;

ADOLESCENT; ADULT; AGED; ANIMAL BEHAVIOR; AREA UNDER THE CURVE; ARTICLE; BLOOD; BONE MARROW; CELL SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT; EX VIVO STUDY; FEMALE; FUCOSYLATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LABORATORY; MALE; MICROVASCULATURE; MYELOABLATIVE CONDITIONING; NEUTROPHIL; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; PROTEIN EXPRESSION; REDUCED INTENSITY CONDITIONING; SAFETY; STEM CELL; SURVIVAL; THROMBOCYTE; COHORT ANALYSIS; CYTOLOGY; FEASIBILITY STUDY; FETUS BLOOD; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TRANSPLANTATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; COHORT STUDIES; E-SELECTIN; FEASIBILITY STUDIES; FEMALE; FETAL BLOOD; FUCOSE; FUCOSYLTRANSFERASES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; P-SELECTIN; PLATELET TRANSFUSION; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84929206880     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-607366     Document Type: Article

References (42)

1. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012;119(9):1972-1980.
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
3. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339-348.
4. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815-1822.
5. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339(22):1565-1577.
6. Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant. 2011;46(3):323-329.
7. Rocha V, Labopin M, Sanz G, et al Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276-2285.
8. Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110(13):4543-4551.
9. Barker JN, Fei M, Karanes C, et al. Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. Br J Haematol. 2014;168(3):405-412.
10. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343-1347.
11. Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121(5):752-758.
12. Schmitz N, Beksac M, Hasenclever D, et al European Group for Blood and Marrow Transplantation. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100(3):761-767.
13. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996;17(Suppl 3):S5-S6.
14. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232-236.
15. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012;367(24):2305-2315.
16. Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014;345(6203):1509-1512.
17. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014;124(7):3121-3128.
18. Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, Frenette PS. PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. Blood. 2003;102(6):2060-2067.
19. Sackstein R. Engineering cellular trafficking via glycosyltransferase-programmed stereosubstitution. Ann N Y Acad Sci. 2012;1253:193-200.
20. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-689.
21. Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci USA. 1998;95(24):14423-14428.
22. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med. 1998;188(3):465-474.
23. Carlow DA, Gossens K, Naus S, Veerman KM, Seo W, Ziltener HJ. PSGL-1 function in immunity and steady state homeostasis. Immunol Rev. 2009;230(1):75-96.
24. Hidalgo A, Weiss LA, Frenette PS. Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally. J Clin Invest. 2002;110(4):559-569.
25. Xia L, McDaniel JM, Yago T, Doeden A, McEver RP. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood. 2004;104(10):3091-3096.
26. Hidalgo A, Frenette PS. Enforced fucosylation of neonatal CD34+ cells generates selectin ligands that enhance the initial interactions with microvessels but not homing to bone marrow. Blood. 2005;105(2):567-575.
27. Robinson SN, Simmons PJ, Thomas MW, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol. 2012;40(6):445-456.
28. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood. 2011;118(26):6743-6751.
29. Ohmori K, Fukui F, Kiso M, et al. Identification of cutaneous lymphocyte-associated antigen as sialyl 6-sulfo Lewis X, a selectin ligand expressed on a subset of skin-homing helper memory T cells. Blood. 2006;107(8):3197-3204.
30. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I; International Society of Hematotherapy and Graft Engineering. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother. 1996;5(3):213-226.
31. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
32. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
33. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
34. Fine JGR. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
35. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120(4):905-913.
36. Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854-2863.
37. Chen YB, Aldridge J, Kim HT, et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012;18(5):805-812.
38. Wagner JE, Brunstein CG, McKenna D, et al. Safety and exploratory efficacy of ex vivo expanded umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) using cytokines and stem-regenin 1 (SR1): interim results of a phase 1/2 dose escalation clinical study Blood. 2014;124(21). Abstract 698.
39. Barao I, Murphy WJ. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant. 2003;9(12):727-741.
40. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
41. Fugier-Vivier IJ, Rezzoug F, Huang Y, et al. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med. 2005;201(3):373-383.
42. Cutler C, Multani P, Robbins D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013;122(17):3074-3081.